ReviewCells2020
Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- The CXCL5/CXCR2 Axis Attenuates Ferroptosis in Intrahepatic Cholangiocarcinoma Through the Positive Feedback Loop Between PTGS2 Transcriptional Activation and Neutrophil Recruitment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Silencing serine/arginine-rich splicing factor 1 to induce apoptosis and autophagy-dependent cell death in cholangiocarcinoma through the correction of oncogenic splicing errors.Anatomy & cell biology · 2025Article
- Autophagy in cholangiocarcinoma: a comprehensive review about roles and regulatory mechanisms.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- MiR-200b-3p elevates 5-FU sensitivity in cholangiocarcinoma cells via autophagy inhibition by targeting KLF4.Non-coding RNA research · 2024Article
- Comprehensive evaluation of cell death-related genes as novel diagnostic biomarkers for breast cancer.Heliyon · 2023Article
- Autophagy Modulation and Its Implications on Glioblastoma Treatment.Current issues in molecular biology · 2023Review
- Active Autophagy Is Associated with Favorable Outcome in Patients with Surgically Resected Cholangiocarcinoma.Cancers · 2023Article
- The new insights into autophagy in thyroid cancer progression.Journal of translational medicine · 2023Review
- Article
- Current Understanding of Flavonoids in Cancer Therapy and Prevention.Metabolites · 2023Review
- COTE1 Facilitates Intrahepatic Cholangiocarcinoma Progression via Beclin1-Dependent Autophagy Inhibition.BioMed research international · 2023Article
- Autophagy impairment in human bile duct carcinoma cells.Frontiers in physiology · 2023Article
- Precision Medicine in Cholangiocarcinoma: Past, Present, and Future.Life (Basel, Switzerland) · 2022Review
- Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation.Stem cells international · 2022Article
- Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy.World journal of gastrointestinal oncology · 2021Review
- Autophagy promotes invadopodia formation in human ovarian cancer cells via the p62-extracellular signal-regulated kinase 1/2 pathway.Experimental and therapeutic medicine · 2021Article
- Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract ofJournal of traditional and complementary medicine · 2021Article
- Flavonoids: A Myth or a Reality for Cancer Therapy?Molecules (Basel, Switzerland) · 2021Review
- Autophagy activity in cholangiocarcinoma is associated with anatomical localization of the tumor.PloS one · 2021Article
- Identification and Validation of Three Autophagy-Related Long Noncoding RNAs as Prognostic Signature in Cholangiocarcinoma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy is a multistep catabolic process through which misfolded, aggregated or mutated proteins and damaged organelles are internalized in membrane vesicles called autophagosomes and ultimately fused to lysosomes for degradation of sequestered components. The multistep nature of the process offers multiple regulation points prone to be deregulated and cause different human diseases but also offers multiple targetable points for designing therapeutic strategies. Cancer cells have evolved to use autophagy as an adaptive mechanism to survive under extremely stressful conditions within the tumor microenvironment, but also to increase invasiveness and resistance to anticancer drugs such as chemotherapy. This review collects clinical evidence of autophagy deregulation during cholangiocarcinogenesis together with preclinical reports evaluating compounds that modulate autophagy to induce cholangiocarcinoma (CCA) cell death. Altogether, experimental data suggest an impairment of autophagy during initial steps of CCA development and increased expression of autophagy markers on established tumors and in invasive phenotypes. Preclinical efficacy of autophagy modulators promoting CCA cell death, reducing invasiveness capacity and resensitizing CCA cells to chemotherapy open novel therapeutic avenues to design more specific and efficient strategies to treat this aggressive cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.